{"organizations": [], "uuid": "64826fa2b23f413ef5ad9bce0cd0dd5b6a801727", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ligand-enters-into-worldwide-omnia/brief-ligand-enters-into-worldwide-omniab-platform-license-agreement-with-ferring-pharmaceuticals-idUSFWN1PH0VB", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T16:08:00.000+02:00", "replies_count": 0, "uuid": "64826fa2b23f413ef5ad9bce0cd0dd5b6a801727"}, "author": "", "url": "https://www.reuters.com/article/brief-ligand-enters-into-worldwide-omnia/brief-ligand-enters-into-worldwide-omniab-platform-license-agreement-with-ferring-pharmaceuticals-idUSFWN1PH0VB", "ord_in_thread": 0, "title": "BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals", "locations": [], "entities": {"persons": [{"name": "ferring", "sentiment": "none"}], "locations": [], "organizations": [{"name": "ligand pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ligand", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "ferring pharmaceuticals reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 22, 2018 / 2:10 PM / Updated 7 minutes ago BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals Reuters Staff \nJan 22 (Reuters) - Ligand Pharmaceuticals Inc: \n* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS \n* LIGAND PHARMACEUTICALS INC - ‍UNDER LICENSE, FERRING WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND BISPECIFIC ANTIBODIES​ \n* LIGAND PHARMACEUTICALS INC - ‍FERRING WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​ \n* LIGAND PHARMACEUTICALS-WITH DEAL WITH FERRING, CO‍ ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T16:08:00.000+02:00", "crawled": "2018-01-22T16:19:59.033+02:00", "highlightTitle": ""}